Research LetterJournal of Pharmacology and PharmacotherapeuticsVol. 8 | Issue 3 | 2017 | pp. 132–133Open access
Cardiac Safety of High-dose Micafungin
- 1,2*,
- 1,2
- 1 Department of Pharmacy Practice, Division of Infectious Diseases, University of Mississippi Medical Center, University of Mississippi School of Pharmacy, Oxford, USA.
- 2 Division of Infectious Diseases, University of Mississippi Medical Center, St. Dominic‑Jackson Memorial Hospital, Jackson, MS, USA.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Kayla R. Stover
Department of Pharmacy Practice, Division of Infectious Diseases, University of Mississippi Medical Center, University of Mississippi School of Pharmacy, Oxford, USA.; Division of Infectious Diseases, University of Mississippi Medical Center, St. Dominic‑Jackson Memorial Hospital, Jackson, MS, USA.
Email: kstover@umc.edu
Copyright: © 2017 Manuscript Technomedia LLP. This is an open access article.
- Published:
- Jan 1, 2017
- Received:
- Mar 31, 2017
- Accepted:
- Aug 9, 2017
How to cite
Stover, K. R., & Cleary, J. D. (2017). Cardiac Safety of High-dose Micafungin. Journal of Pharmacology and Pharmacotherapeutics, 8(3), 132–133. https://doi.org/10.4103/jpp.JPP_37_17
Abstract
Pharmacotherapy in patients with systemic fungal infections continues to challenge the heartiest clinicians. The inability of the antimycotic to discriminate the infected eukaryotic host from the pathogen often leads to treatment‑limiting adverse events. In our continued efforts to improve the safety of antifungal therapy, we initiated studies to evaluate the dose, onset, peak, and duration of echinocandin‑induced cardiomyopathy. Over the past 5–6 years, a plethora of animal data and case reports has been published that describes this phenomenon. First, we performed ex vivo studies in an attempt to elucidate the toxicity of the echinocandin antifungals. Clear decreases in cardiac contractility were observed in adult male Sprague‑Dawley rat hearts after infusion of caspofungin and anidulafungin. To determine whether these displayed effects would translate to a live model, we performed in vivo studies in live, adult male Sprague‑Dawley rats. Blood pressure and echocardiography were evaluated before, during, and after a 10‑minute central infusion of caspofungin, anidulafungin, or micafungin. At doses known to replicate human pharmacologic exposures, caspofungin and anidulafungin were associated with significant decreases in cardiac output (CO). No changes were seen with micafungin. In a similar in vivo rat model, investigators evaluated the effect of high (8.75–30 mg/kg)‑ and low‑dose (0.875–3 mg/kg) echinocandin administration on cardiac function. Their results were similar to those described above: high‑dose anidulafungin and caspofungin showed immediate hemodynamic decreases, while animals treated with micafungin had no impact on cardiac function. Finally, several clinical reports of toxicity associated with these agents, ranging from pulmonary edema to cardiac decompensation, have substantiated this previous research. The purpose of this study was to expand assessments of cardiac toxicity to include a wider array of doses of micafungin to define dose and onset of this adverse event.
Keywords
Subject
Article metadata
| Title | Cardiac Safety of High-dose Micafungin |
|---|---|
| Authors | Kayla R. Stover; John D. Cleary |
| Affiliations | Department of Pharmacy Practice, Division of Infectious Diseases, University of Mississippi Medical Center, University of Mississippi School of Pharmacy, Oxford, USA.; Division of Infectious Diseases, University of Mississippi Medical Center, St. Dominic‑Jackson Memorial Hospital, Jackson, MS, USA. |
| Corresponding author | kstover@umc.edu |
| Journal | Journal of Pharmacology and Pharmacotherapeutics |
| Volume / Issue | Vol. 8, Issue 3 (2017) |
Also in this issue
- An Overview of the Extraarticular Involvement in Rheumatoid Arthritis and its Managementpp. 81–86
- Retrospection on the Role of Soluble Guanylate Cyclase in Parkinson’s Diseasepp. 87–91
- Biological Response Modifiers in Rheumatoid Arthritis: Systematic Review and Meta‑analysis of Safetypp. 92–105
- Efficacy and Tolerability of Olmesartan, Telmisartan, and Losartan in Patients of Stage I Hypertension: A Randomized, Open‑label Studypp. 106–111
- Effect of Lorazepam in Reducing Psychological Distress and Anticipatory Nausea and Vomiting in Patients Undergoing Chemotherapypp. 112–5
Readers Also Viewed
Development and Validation of UV/visible Spectrophotometric Method for Estimation of Piroxicam from Bulk and Formulation
Sandip Mohan Honmane, Kunal Rajaram Yadav, Yuvraj Dilip Dange
Apr 23, 2025
Effects of Artificial Intelligence on Academic Performance of Library and Information Science University Students: A Meta-Analysis (2023-2025)
Kayode Sunday John Dada
Aug 6, 2026
Bridging Innovation and Impact: A Multidisciplinary Approach to Contemporary Research Challenges
Mueen Ahmed KK
Aug 11, 2026